TY  - GEN
AU  - Catenacci,Daniel V T
AU  - Tebbutt,Niall C
AU  - Davidenko,Irina
AU  - Murad,André M
AU  - Al-Batran,Salah-Eddin
AU  - Ilson,David H
AU  - Tjulandin,Sergei
AU  - Gotovkin,Evengy
AU  - Karaszewska,Boguslawa
AU  - Bondarenko,Igor
AU  - Tejani,Mohamedtaki A
AU  - Udrea,Anghel A
AU  - Tehfe,Mustapha
AU  - De Vita,Ferdinando
AU  - Turkington,Cheryl
AU  - Tang,Rui
AU  - Ang,Agnes
AU  - Zhang,Yilong
AU  - Hoang,Tien
AU  - Sidhu,Roger
AU  - Cunningham,David
TI  - Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
SN  - 1474-5488
PY  - 2017///1215
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - adverse effects
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Capecitabine
KW  - Cisplatin
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Epirubicin
KW  - Esophageal Neoplasms
KW  - drug therapy
KW  - Esophagogastric Junction
KW  - pathology
KW  - Humans
KW  - Internationality
KW  - Kaplan-Meier Estimate
KW  - Middle Aged
KW  - Prognosis
KW  - Proportional Hazards Models
KW  - Proto-Oncogene Proteins c-met
KW  - drug effects
KW  - Stomach Neoplasms
KW  - Survival Analysis
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(17)30566-1
ER  -